O'Brien SG - Search Results

1

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, Foot N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, O'Brien SG, Goldman JM, Apperley JF. Marin D, et al. Leukemia. 2003 Aug;17(8):1448-53. doi: 10.1038/sj.leu.2402996. Leukemia. 2003. PMID: 12886230

2

Options for therapy in chronic myeloid leukaemia.

Spencer A, O'Brien SG, Goldman JM. Spencer A, et al. Br J Haematol. 1995 Sep;91(1):2-7. doi: 10.1111/j.1365-2141.1995.tb05236.x. Br J Haematol. 1995. PMID: 7577633 Review. No abstract available.

3

Autografting in chronic myeloid leukaemia.

O'Brien SG, Goldman JM. O'Brien SG, et al. Blood Rev. 1994 Jun;8(2):63-9. doi: 10.1016/s0268-960x(05)80009-8. Blood Rev. 1994. PMID: 7950476 Review.

4

Residual Ph-negative stem cells in chronic myeloid leukemia--sometimes or always?

Goldman JM, O'Brien SG. Goldman JM, et al. Stem Cells. 1993 Oct;11 Suppl 3:4-7. doi: 10.1002/stem.5530110903. Stem Cells. 1993. PMID: 8298477 Review.

5

Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.

O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM. O'Brien SG, et al. Leukemia. 1994 Dec;8(12):2156-62. Leukemia. 1994. PMID: 7808004

6

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O'Brien S. Marin D, et al. Blood. 2012 Jul 12;120(2):291-4. doi: 10.1182/blood-2012-01-407486. Epub 2012 May 29. Blood. 2012. PMID: 22645182 Free article. Clinical Trial.

7

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D. Neelakantan P, et al. Blood. 2013 Apr 4;121(14):2739-42. doi: 10.1182/blood-2012-11-466037. Epub 2013 Feb 4. Blood. 2013. PMID: 23380743 Free PMC article. Clinical Trial.

8

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L. Grinfeld J, et al. Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10. Br J Haematol. 2013. PMID: 24117365 Free article.

9

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.

Alonso-Dominguez JM, Grinfeld J, Alikian M, Marin D, Reid A, Daghistani M, Hedgley C, O'Brien S, Clark RE, Apperley J, Foroni L, Gerrard G. Alonso-Dominguez JM, et al. Am J Hematol. 2015 Jan;90(1):20-6. doi: 10.1002/ajh.23857. Epub 2014 Oct 18. Am J Hematol. 2015. PMID: 25250944 Free article.

10

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.

Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM, O'Brien S. Gallipoli P, et al. Br J Haematol. 2022 Mar;196(6):e55-e57. doi: 10.1111/bjh.17961. Epub 2022 Jan 6. Br J Haematol. 2022. PMID: 34993961 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters